Pharmanest Initiates Phase II Study of SHACT
News Jun 19, 2012
Pharmanest AB has announced that the first patient has been dosed in a randomized Phase II study of SHACT, a product developed for pain relief associated with intrauterine device (IUD) insertion. Karolinska Development AB owns 58.9 percent of Pharmanest.
All patients in the initial Phase I study with SHACT are included and the first patient has now received a dose in a double-blind, randomized, placebo-controlled Phase II study.
The goal of the Phase II study is to evaluate the effect of SHACT in connection with IUD insertion in women. Secondary objectives include evaluating safety and tolerability.
Gunilla Lundmark, CEO of Pharmanest: "The results from this study will be an important step closer to a possible new local anesthetic product. Many women experience pain associated with IUD insertion and there are few local anesthetic products on the market with proven efficacy in this indication. We see a great need for SHACT associated with IUD insertion as well as for other gynecological procedures."
SHACT is applied topically in the cervix and uterus with devices developed by Pharmanest. The goal is to achieve immediate pain relief without the need for advanced equipment.
The Phase II study is expected to enroll approximately 200 patients and will be conducted at the Karolinska University Hospital. Principal Investigator is Dr. Sara Törnblom Paulander, a specialist in obstetrics and gynecology.
Torbjörn Bjerke, CEO of Karolinska Development and board member of Pharmanest: "We are very pleased that Pharmanest takes the next important step in the development of SHACT. This is a product that addresses a clear medical need among the millions of women worldwide inserting IUD each year."
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B TreatmentNews
All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.READ MORE